Canine cognitive dysfunction syndrome: Prevalence, clinical signs and treatment with a neuroprotective nutraceutical

Applied Animal Behaviour Science

Volumn 105, Issue 4, 2007, Pages 297-310

  Osella, Maria Cristina ^a   Re, Giovanni ^a   Odore, Rosangela ^a   Girardi, Carlo ^a   Badino, Paola ^a   Barbero, Raffaella ^a   Bergamasco, Luciana ^a  

^a Facolta di Medicina Veterinaria   (Italy)

Author keywords

Ageing; Cognitive dysfunction; Dementia; Dog; Neuroprotection; Nutraceutical

Indexed keywords

AGE; BEHAVIOR; CANID; DISEASE PREVALENCE; FOOD; QUESTIONNAIRE SURVEY;

CANIS FAMILIARIS; GINKGO BILOBA;

EID: 34249331692     PISSN: 01681591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.applanim.2006.11.007     Document Type: Article

References (97)

1. Adams B., Chan A., Callahan H., and Milgram N.W. The canine as a model of human cognitive agent: recent developments. Prog. Neuro-Psychopharm. Biol. Psychiat. 24 (2000) 675-692
2. Anderson A.J., Ruehl W.W., Fleischmann L.K., Stenstrom K., Entriken T.L., and Cummings B.J. DNA damage and apoptosis in the aged canine brain: relationship to Abeta deposition in the absence of neuritic pathology. Prog. Neuropsychopharm. Biol. Psychiat. 24 (2000) 787-799
3. Anderson I., Adinolfi C., and Doctrow S. Oxidative signalling and inflammatory pathways in Alzheimer's disease. Biochem. Soc. Symp. 67 (2001) 141-149
4. Araujo J.A., Studzinski C.M., and Milgram N.W. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog. Neuropsychopharm. Biol. Psychiat. 29 (2005) 411-422
5. Arnsten, A.F.T., 1993. Catecholamine mechanisms in age-related cognitive decline. Neurobiol. Ag. 14, 639-641.
6. Bain M.J., Hart B.L., Cliff K.D., and Ruehl W.W. Predicting behavioral changes associated with age-related cognitive impairment in dogs. JAVMA 218 (2001) 1792-1795
7. Baker G.B., and Reynolds G.P. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. Neurosci. Lett. 100 (1989) 335-339
8. Bastianetto S., and Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol. Ag. 23 (2002) 891-897
9. Behl C., and Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic. Biol. Med. 33 (2002) 182-191
10. Blokland A., Honig W., Brouns F., and Jolles J. Cognition-enhancing properties of subchronic phosphatidylserine (PS) treatment in middle-aged rats: comparison of bovine cortex PS with egg PS and soybean PS. Nutrition 15 10 (1999) 778-783
11. Borras D., Ferrer I., and Pumarola M. Age-related changes in the brain of the dog. Vet. Pathol. 36 (1999) 201-211
12. Campbell S., Trettien A., and Kozan B. A non comparative open-label study evaluating the effect of selegiline hydrocloride in a clinical setting. Vet. Ther. 2 (2001) 24-39
13. Cenacchi T., Baggio C., and Palin E. Human tolerability of oral phosphatidylserine assessed through laboratory examinations. Clin. Trials J. 24 (1987) 125-130
14. Cenacchi T., Bertoldin T., and Farina C. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Ag. Clin. Exp. Res. 5 (1993) 123-133
15. Chan A.D., Nippak P.M., Murphey H., Ikeda-Douglas C.J., Muggenburg B., Head E., Cotman C.J., and Milgram N.W. Visuospatial impairments in aged canines (Canis familairis): the role of cognitive behavioral therapy. Behav. Neurosci. 116 (2002) 443-454
16. Chapman B.L., and Voith V.L. Behavioral problems in old dogs: 26 cases (1984-1987). JAVMA 6 (1990) 944-946
17. Chopin P., and Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology (Berl) 106 (1992) 26-30
18. Cohen S.A., and Mueller W.E. Age-related alterations of NMDA-receptor properties in the mouse forebrain: partial restoration by chronic phosphatidylserine dosing. Brain Res. 584 (1992) 174-180
19. Colle A.A., Hauw J.J., Crespeau F., Uchihara T., Akiyama H., Cheeler F., Pageat P., and Duykaerts C. Vascular and parenchimal Aâ deposition in the aging dog: correlation with behaviour. Neurobiol. Ag. 21 (2000) 695-704
20. Cotman C.W., Head E., Muggenburg B.A., Zicker S., and Milgram N.W. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol. Ag. 23 (2002) 809-818
21. Crook K.T., Petrie W., Wells C., and Massari D.C. Effects of phosphatidylserine in Alzheimer disease. Psychopharmacol. Bull. 28 (1992) 61-66
22. Cummings B.J., Head E., Ruehl W., Milgram N.W., and Cotman C.W. The canine model as an animal model of human aging and dementia. Neurobiol. Ag. 17 (1996) 259-268
23. Dakshinamurti K., Paulose C.S., and Siow Y.L. Neurobiology of pyridoxine. In: Reynolds R.D., and Leklem J.E. (Eds). Vitamin B6: Its Role in Health and Disease (1995), Alan R Liss Inc., New York 99-121
24. DeFeudis F.V., and Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr. Drug Targets 1 (2000) 25-58
25. Dimakopoulos A.C., and Mayer R.J. Aspects of neurodegeneration in the canine brain. J. Nutr. 132 (2002) 1579S-1582S
26. Dodman N.H. Geriatric behavior problems. In: Dodman N.H., and Shuster L. (Eds). Psychopharmacology of Animal Behavior Disorders (1998), Blacwell Science, Malden 279-282
27. Fukuoka A., Nakayama H., and Doi K. Immunohistochemical detection of beta-amyloid and beta-amyloid precursor protein in the canine brain and non-neuronal epithelial tissues. Amyloid 11 (2004) 173-178
28. Gelbmann C.M., and Muller W.E. Chronic treatment with phosphatidylserine restores muscarinic cholinergic receptor deficits in the aged mouse brain. Neurobiol. Ag. 13 (1992) 45-50
29. Gertz H.J., and Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr. Pharm. Des. 10 (2004) 261-264
30. Gonzalez-Soriano J., Marin Garcia P., Contreras-Rodriguez J., Martinez-Sainz P., and Rodriguez-Veiga E. Age-related changes in the ventricular system of the dog brain. Ann. Anat. 183 (2001) 283-291
31. Guerriero A.L., Dorado-Martinez C., and Rodriguez A. Effects of vitamin E on ozoneinduced memory deficits and lipid peroxidation in rats. Neuroreport 10 8 (1999) 1689-1692
32. Head E., Hartley J., and Kameka A.M. The effects of l-deprenyl on spatial short term memory in young and aged dogs. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 20 (1996) 515-530
33. Head E., Callahan H., Cummings B.J., Cotman C.W., Ruehl W.W., Muggenberg B.A., and Milgram N.W. Open field activity and human interaction as a function of age and breed in dogs. Physiol. Behav. 62 (1997) 963-971
34. Head E., Thornton P.L., Tong L., and Cotman C.W. Initiation and propagation of molecular cascades in human brain aging: insight from the canine model to promote successful aging. Prog Prog. Neuropsychopharm. Biol. Psychiat. 24 (2000) 777-786
35. Head E., Liu J., Hagen T.M., Muggenburg B.A., Milgram N.W., Ames B.N., and Cotman C.W. Oxidative damage increases with age in a canine model of human brain aging. J. Neurochem. 82 (2002) 375-381
36. Head E., and Zicker S.C. Nutraceuticals, aging, and cognitive dysfunction. Vet. Clin. North Am. Small Anim. Pract. 34 (2004) 217-228
37. Heywood R., Cozens D.D., and Richold M. Toxicology of a phosphatidylserine preparation from bovine brain (BC-PS). Clin. Trials J. 24 (1987) 25-32
38. Hoffman J.R., Donato A., and Robbins S.J. Ginkgo biloba promotes short-term retention of spatial memory in rats. Pharmacol. Biochem. Behav. 77 (2004) 533-539
39. Houpt K.A., and Beaver B. Behavioral problems of geriatric dogs and cats. Vet. Clin. North Am. Small Anim. Pract. 35 (1981) 643-652
40. Huguet F., and Tarrade T. Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba extract. J. Pharm. Pharmacol. 44 (1992) 24-27
41. Huguet F., Drieu K., and Piriou A. Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J. Pharm. Pharmacol. 46 4 (1994) 316-318
42. Kalaria R.N., Andorn A.C., and Harik S.I. Alterations in adrenergic receptors of frontal cortex and cerebral microvessels in Alzheimer's disease and aging. Prog. Clin. Biol. Res. 317 (1989) 367-374
43. Kalaria R.N., and Andorn A.C. Adrenergic receptors in aging and Alzheimer's disease: decreased alpha2-receptors demonstrated by 3Hp-aminoclonidine binding in prefrontal cortex. Neurobiol. Ag. 12 (1991) 131-136
44. Kiatipattanasakul W., Nakamura S., and Hossain M.M. Apoptosis in the aged dog brain. Acta Neuropathol. 92 (1996) 242-248
45. Kumar A.M., Sevush S., and Kumar M. Peripheral serotonin in Alzeimer's disease. Neuropshychobiology 32 (1995) 9-12
46. Lai M.K., Tsang S.W., and Francis P.T. Post-mortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 13 (2002) 1175-1178
47. Landsberg G.M., Hunthausen W., and Ackerman L. The effects of aging on the behavior of senior pets. In: Landsberg G.M., Hunthausen W., and Ackerman L. (Eds). Handbook of Behavior Problems of the Dog and Cat. 2nd ed. (2003), Saunders, Edinburgh 269-304
48. Landsberg G. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Prog. Prog. Neuropsychopharm. Biol. Psychiat. 29 3 (2005) 471-479
49. Landsberg G., and Ruehl W. Geriatric behavioural problems. In: Houpt K. (Ed). The Veterinary Clinics of North America: Small Animal Practice (1997), WB Saunders, Philadelphia 1537-1559
50. Landsberg G., and Araujo J.A. Behavior problems in geriatric pets. Vet. Clin. North Am. Small Anim. Pract. 35 (2005) 675-698
51. Le Bars P.L., Velasco F.M., and Ferguson J.M. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba Egb761 in Alzheimer's disease. Neuropsychobiology 45 (2002) 19-26
52. Lee T.F., Chen C.F., and Wang L.C. Effect of ginkgolides on beta-amyloid-suppressed acetylcholine release from rat hippocampal slices. Phytother. Res. 18 (2004) 556-560
53. Lockhart B.P., and Lestage P.J. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?. Exp. Gerontol. 38 (2003) 119-128
54. Magnusson K.R., Scanga C., Wagner A.E., and Dunlop C. Changes in anesthetic sensitivity and glutamate receptors in the aging canine brain. J. Gerontol. A Biol. Sci. Med. Sci. 55 (2000) 448-454
55. McKenna D.J., Jones K., and Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern. Ther. Health Med. 7 (2001) 70-86
56. Meana J.J., Barturen F., and Garro M.A. Decreased density of alpha2-adrenoceptors in post-mortem brains of patients with Alzheimer's disease. J. Neurochem. 58 (1992) 1896-1904
57. Milan F., Guidolin D., and Polato P. Structural changes of basal forebrain cholinergic neurons in the aged rat. Effect of phosphatidylserine administration. In: Pepeu G., Tomlinson B., and Wischik C.M. (Eds). New Trends in Aging Research (1988), Liviana Press, Padova, Italy 221-231
58. Milgram N.W., Ivy G.O., Murphy M.P., Head E., WU P.H., Ruhel W.W., Yu P.H., Durden D.A., Davis B.A., and Boulton A.A. Effects of chronic oral administration of L-deprenyl in the dog. Pharmacol. Biochem. Behav. 51 (1995) 421-428
59. Milgram N.W., Head E., Weiner E., and Thomas E. Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav. Neurosci. 108 (1994) 57-68
60. Milgram N.W., Head E., Muggenburg B., Holowachuk D., Murphey H., Estrada J., Ikeda-Douglas C.J., Zicker S.C., and Cotman C.W. Landmark discrimination learning in the dog: effects of age, an antioxidant fortified food, and cognitive strategy. Neurosci. Biobehav. Rev. 26 (2002) 679-695
61. Nathan P. Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology?. Med. Hypotheses 55 6 (2000) 491-493
62. Neilson J.C., Hart B.L., Cliff K.D., and Ruehl W.W. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. JAVMA 218 (2001) 17872-21791
63. Nunzi M.G., Guidolin D., and Petrelli L. Behavioral and morpho-functional correlates of brain aging: a preclinical study with phosphatidylserine. Adv. Exp. Med. Biol. 318 (1992) 393-398
64. Overall K.L. Natural animal models of human psychiatric conditions: assessment of mechanism and validity. Prog. Prog. Neuropsychopharm. Biol. Psychiat. 24 (2000) 727-776
65. Overall K.L. Pharmacological treatment in behavioural medicine: the importance of neurochemistry, molecular biology and mechanistic hypotheses. Vet. J. 162 (2001) 9-23
66. Overall K.L. Canine brain aging: from diagnosis to management. Proceedings of the 27th WSAVA World Congress. Granada, Spain, October (2002) 25-30
67. Pageat P. Description, clinical and histological validation of the A.R.C.A.D. score (evaluation of age-related cognitive and affective disorders). In: Overall K.L. (Ed). Proceedings of the Third International Congress on Veterinary Behavioral Medicine (2001) 83-88
68. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration 5 (1996) 381-391
69. Papaioannou N., Tooten P.C., van Ederen A.M., Bohl J.R., Rofina J., Tsangaris T., and Gruys E. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 8 (2001) 11-21
70. Pugliese P., Carrasco J.L., Andrade C., Mas E., Mascort J., and Mahy N. Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia Prog. Neuro-Psychopharmacol. Biol Psychiat. 24 (2005) 675-692
71. Raitieri M., Caviglia A.M., Marchi M., Maura G., and Pittaluga A. Changes of neurotransmitter release in the old rat brain and effects of phosphatidylserine treatment. In: Pepeu G., Tomlinson B., and Wischik C.M. (Eds). New Trends in Aging Research (1988), Liviana Press, Padua 21-26
72. Reinikainen K.J., Soininen H., and Riekkinen P.J. Neurotrasmitter changes in Alzheimer's disease implications to diagnostics and therapy. J. Neurosci. Res. 27 (1990) 576-586
73. Rinne J.O. Muscarinic and dopaminergic receptors in ageing human brain. Brain Res. 404 (1987) 161-168
74. Rofina J.E., Singh K., Skoumalova-Vesela A., van Ederen A.M., van Asten A.J., Wilhelm J., and Gruys E. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 11 (2004) 90-100
75. Ruehl W.W., Bruyette D.S., DePaoli A., Cotman C.W., Head E., Milgram N.W., and Cummings B. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to l-deprenyl therapy. Prog. Brain Res. 106 (1995) 217-225
76. Ruehl W.W., and Hart B.L. Canine cognitive dysfuntion. In: Dodman N.H., and Shuster L. (Eds). Psychopharmacology of Animal Behavior Disorders (1998), Blacwell Science, Malden 283-304
77. Samson J.C. The biological basis of phosphatidylserine pharmacology. Clin. Trials J. 24 (1987) 1-8
78. Sano M., Ernesto C., and Thomas R.G. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 17 (1997) 1216-1222
79. Sastre J., Millan A., and Garcia de la Asuncion J. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic. Biol. Med. 24 (1998) 298-304
80. Sastre M., Guimon J., and Garcia-Sevilla J.A. Relationship between beta- and alpha2-adrenoceptors and G coupling proteins in the human brain: effects of age and suicide. Brain Res. 898 (2001) 242-255
81. Siwak C.T., Tapp P.D., and Milgram N.W. Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem. 8 (2001) 317-325
82. Siwak C.T., Murphey H.L., Muggenburg B.A., and Milgram N.W. Age-dependent declines in locomotor activity in canines is environment specific. Physiol. Behav. 75 1-2 (2002) 65-70
83. Siwak C.T., Tapp P.D., Murphey H.L., Zicker S.C., Muggenburg B.A., Head E., Cotman C.W., and Milgram N.W. Locomotor activity rhytms in dogs vary with age and cognitive function. Behav. Neurosci. 117 4 (2003) 813-824
84. Skoumalova A., Rofina J., Schwippelova Z., Gruys E., and Wilhelm J. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp. Gerontol. 38 (2003) 711-719
85. Studzinski C.M., Araujo J.A., and Milgram N.W. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog. Prog. Neuropsychopharm. Biol. Psychiat. 29 (2005) 489-498
86. Suzuki S., Furushiro M., and Takahashi M. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine (SB-tPS) reduces ischemic damage in the gerbil hippocampus. Jpn. J. Pharmacol. 81 (1999) 237-239
87. Suzuki S., Yamatoya H., and Sakai M. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. J. Nutr. 131 (2001) 2951-2956
88. Tapp P.D., Siwak C.T., Estrada J., Head E., Muggenburg B.A., Cotman C.W., and Milgram N.W. Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem. 10 (2003) 64-73
89. Taylor J.E. Binding of neuromediators to their receptors in rat brain. Effect of chronic administration of Ginkgo biloba extract. Presse Med. 15 (1986) 1491-1493
90. Tohgi H., Abe T., and Takahashi S. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett. 141 (1992) 9-12
91. Tsakiris S., and Deliconstantinos G. Influence of phosphatidylserine on (Na+ + K+)-stimulated ATPase and acetylcholinesterase activities of dog brain synaptosomal plasma membranes. Biochem. J. 220 (1984) 301-307
92. 2+-stimulated ATPase activity of dog brain synaptosomal plasma membranes. Int. J. Biochem. 17 (1985) 1117-1119
93. Vannucchi M.G., Casamenti F., and Pepeu G. Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by phosphatidylserine. J. Neurochem. 55 (1990) 819-825
94. Wells D.L., and Hepper P.G. Prevalence of behaviour problems reported by owners of dogs purchased from an animal rescue shelter. Appl. Anim. Behav. Sci. 69 (2000) 55-65
95. White H.L., Scates P.W., and Cooper B.R. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci. 58 (1996) 1315-1321
96. Yamatoya H., Sakai M., and Kudo S. The effects of soybean transphosphatidylated phosphatidylserine on cholinergic synaptic functions of mice. Jpn. J. Pharmacol. 84 (2000) 93-96
97. Yao Z., Drieu K., and Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889 (2001) 181-190